Introduction {#s5}
============

As ligand-gated excitatory cation channels, nicotinic acetylcholine receptors (nAChRs) in central nervous system (CNS) are fundamental to physiology ([@CIT0035]). The 2 nicotinic receptor subtypes, α4β2 and α7, predominate in CNS among many other nAChR subtypes ([@CIT0035]; [@CIT0024]). Nicotine binds with high affinity to α4β2-nAChR (*K*~I~ \~ 1 nM; [@CIT0004]) and with a much lower affinity to α7-nAChR (*K*~I~ \~ 6000--14000 nM; [@CIT0010]).

The α7-nAChR subtype is associated with the pathophysiology of specific CNS diseases, including schizophrenia, drug addiction, depression, anxiety, and multiple neurodegenerative disorders ([@CIT0055], [@CIT0054]; [@CIT0064]; [@CIT0003]; [@CIT0013]; [@CIT0047]; [@CIT0027]; [@CIT0030]; [@CIT0044]) and therefore is an important target of drug discovery. Multiple postmortem studies have shown reduced α7 receptors in brain samples from patients with schizophrenia, suggesting a role of α7 in schizophrenia (see review by [@CIT0052]). In autoradiography of brains from patients with schizophrenia, reductions of α-\[^125^I\] BTX binding to α7 were demonstrated in hippocampus, anterior cingulate cortex, and thalamic reticular nucleus ([@CIT0018]) but not in orbitofrontal or temporal lobes ([@CIT0009]; [@CIT0039]).

The α7-nAChR has emerged as a potential therapeutic target for treatment of schizophrenia ([@CIT0058]; [@CIT0002]; [@CIT0021]; [@CIT0056]; [@CIT0065]a; [@CIT0017]b; [@CIT0006]). In animals, stimulation of α7 is procognitive ([@CIT0065]a; [@CIT0048]). In clinical trials with selective α7 agonists, activation of the receptor improved cognitive performance in patients with schizophrenia. Selected drugs (DMXB-A, also known as GTS-21, TC-5619, and EVP-6124) show some degree of cognitive improvement in trials of patients with schizophrenia, although none has yet proceeded to late phase or FDA approval. A common trend is the improvement of cognition with an inverted U-shaped dose--response curve, when increasing the dose of α7 agonist above a threshold resulted in loss of drug effect ([@CIT0057]; [@CIT0034]). The latest research has revealed a new generation of promising α7-targeting drugs ([@CIT0007]).

Despite the importance of the nicotinic receptor system, the physiological and pharmacological roles of specific receptor subtypes in CNS remain poorly understood ([@CIT0047]; [@CIT0030]; [@CIT0037]; [@CIT0044]). Until recently, the lack of radioligands for quantitative emission tomography imaging of α7-nAChR in humans hampered noninvasive research of this receptor system. Many radiotracers of interest to α7-nAChR (^11^C-CHIBA-1001; [@CIT0053]), ^11^C-NS14492 ([@CIT0014]; [@CIT0036]), and others have been tested, but most had suboptimal properties in PET of humans (see [@CIT0020] for review). Here, we further tested human subjects with \[^18^F\]ASEM, the only α7-nAChR PET tracer available to humans with promising imaging characteristics ([@CIT0020]; [@CIT0029]; [@CIT0028]; [@CIT0008]; [@CIT0026]; [@CIT0063]). Objectives included: (1) confirmation of test-retest reproducibility of \[^18^F\]ASEM binding in brain of normal volunteers, (2) demonstration for the first time of specific binding and target engagement/occupancy in human brain of the partial agonist DMXB-A (GTS-21), (3) estimation for the first time of \[^18^F\]ASEM binding potentials and α7-nAChR receptor density (*B*~max~) and inhibitor affinity constant (*K*~I~) for human brain *in vivo*, and (4) a feasibility study of the target role of α7-nAChR in psychosis in 6 patients with schizophrenia.

Methods {#s6}
=======

Subjects {#s7}
--------

All studies were carried out with the approval of the Johns Hopkins Institutional Review Board, where all subjects provided written informed consent. Participants were recruited via advertisements within the metropolitan Baltimore region.

Twenty-one healthy, nonsmoking control subjects (13 males and 8 females; age range: 18--52 years; means±SD: 32.6±12.4 years) volunteered for the study. In addition to baseline PET, 12 subjects had a second baseline PET (test-retest), and 5 other subjects had a second PET after a single dose of DMXB-A. Only 8 of the 12 subjects had successful test-retest PET due to technical problems in either test or retest in 4 subjects. Of the subjects, 5 (including 2 with test-retest from a previous publication by [@CIT0062]) were included in this study. Healthy volunteers had no psychotropic treatment history, were free of significant medical or neuropsychiatric disorder, and received no current medications.

To examine the feasibility of measuring α7 nAChR in schizophrenia, 6 patients diagnosed with schizophrenia (aged 20--31 years; average 25.0±4.3 \[SD\] y; all males; 1 smoker only) were recruited. Volunteers with schizophrenia that met DSM-V criteria, with stable antipsychotic medication other than clozapine, were referred by collaborating psychiatrists. Subjects underwent neuropsychiatric characterization including Brief Psychiatric Rating (BPRS) scores. Demographic data for healthy controls and subjects with schizophrenia are listed in [Table 1A](#T1A){ref-type="table"}, [1B](#T1B){ref-type="table"}. Participants provided information of history of tobacco use, including number of cigarettes per day and years of tobacco use.

###### 

Group Demographics

  Diagnosis                     Condition   n    Males   Females       Age (mean/SD)   Age (range)
  ----------------------------- ----------- ---- ------- ------------- --------------- -------------
  Healthy controls^*a*^         Baseline    21   13      8             32.0 (12.4)     18--52
  Retest                        8           6    2       37.8 (11.7)   20--52          
  Blocking                      5           3    2       22.1 (4.5)    18--28          
  Patients with schizophrenia   Baseline    6    6       0             24.8 (3.9)      20--31

^*a*^No healthy controls reported current or past smoking history.

###### 

Patients with Schizophrenia

  Subject ID     Age   Sex   Race   Ethnicity   BPRS -- Negative (M)   BPRS -- Positive (M)   Smoker   Cigarettes/d   Medications
  -------------- ----- ----- ------ ----------- ---------------------- ---------------------- -------- -------------- -----------------------------------------------------
  01             27    M     AA     NH          2.25                   1.25                   No       N/A            Aripiprazole
  02             31    M     W      NH          3                      1                      Yes      20             Haloperidol, benztropine, sertraline
  03             22    M     AA     NH          2.75                   2.25                   No       N/A            Risperidone
  04             25    M     AA     NH          2.75                   1.75                   No       N/A            Quetiapine, haloperidol, benztropine
  05             20    M     AA     NH          1.5                    1.5                    No       N/A            Escitalopram, benztropine, aripiprazole, clonezapam
  06 -- Scan 1   24    M     W      NH          2.75                   3.25                   No       N/A            Risperidone, lorazepam
  06 -- Scan 2   24    M     W      NH          1.0                    1.0                    No       N/A            Lorazepam

All subjects (controls and patients with schizophrenia) had negative urinary toxicology tests and provided CO breath samples of \<4 ppm on the imaging day to confirm abstinence for at least 12 h from tobacco smoking for any subjects (see additional inclusion/exclusion criteria in [Supplemental Material](#sup1){ref-type="supplementary-material"}).

One patient with schizophrenia was tested with PET \[^18^F\]ASEM while chronically treated with risperidone and then retested with PET without drug for 3 weeks (discontinued for clinical reasons).

To address possible effects of antipsychotics administered to patients, we determined biodistribution in mice treated for 5 d with cohorts of placebo vs risperidone, aripiprazole, or olanzapine, the 3 most common drugs in the present patient population, at doses equivalent to doses used in humans ([@CIT0051]; [@CIT0012]; [@CIT0040]; [@CIT0041]). Mice were i.v. injected with \[^18^F\]ASEM and sacrificed after 60 min (detailed Methods and [Figure A](#sup1){ref-type="supplementary-material"} in [Supplemental Materials](#sup1){ref-type="supplementary-material"}).

PET {#s8}
---

All subjects underwent PET with the Siemens/CTI High-Resolution Research Tomography (HRRT: resolution \<2 mm). The dynamic imaging continued for 90 min with the frame sequences of 4x15 s, 4x30 s, 3x60 s, 2x120 s, 5x240 s, and 12x300 s. Each subject received a radial arterial catheter for collection of approximately 40 arterial blood plasma samples and subsequent HPLC radiometabolite detection during the 90-min imaging session. Arterial plasma samples were drawn as rapidly as possible for the first 2 min and then every minute until 10 min post injection, every 2 min until 20 min post injection, and at the times 25, 30, 45, 60, 75, and 90 min post injection. Metabolites were measured for the times of 2, 5, 10, 20, 30, 60, and 90 min post injection. (See [Supplemental Material](#sup1){ref-type="supplementary-material"} for HPLC methods.)

Each subject received 13.8 mCi±0.23 (SEM) \[^18^F\]ASEM synthesized by the method of [@CIT0020] with average specific activity of 56417 Ci/mmol. There were no significant differences in injected radioactivity or specific activity between the controls and patients with schizophrenia. Tracer-free fraction in plasma across subjects averaged 2.79% ± 0.06 (SD) and was not significantly different in healthy controls and patients with schizophrenia (methods in [Supplemental Materials](#sup1){ref-type="supplementary-material"}).

Of the healthy volunteers, 12 were retested with \[^18^F\]ASEM imaging approximately 5 weeks (mean 41.2 d) after the first PET session, including 3 reported by [@CIT0062]. We carefully reviewed the radiometabolite HPLC results and elected to exclude 4 subjects for technical reasons (e.g., defective capture columns during early development of HPLC procedures). To determine the target engagement (occupancy) by a receptor ligand and to obtain evidence of specific binding of \[^18^F\]ASEM to α7-nAChR in humans, 5 healthy subjects additionally underwent a second imaging session after administration of oral 150 mg of the partial agonist DMXB-A, 40 min before the PET tracer injection. Radial arterial samples for detection of concentration DMXB-A were obtained during PET imaging at 70, 100, and 130 min post-oral dose of DMXB-A. Concentrations of DMXB-A in subjects' plasma samples were determined quantitatively by HPLC with a modification of the previously reported method ([@CIT0033]). (Details in [Supplemental Material](#sup1){ref-type="supplementary-material"}.)

Menstrual phase for the women was determined by a progesterone level using levels exceeding 2 ng/mL, indicating luteal phase. For 2 women (one in luteal phase and one in follicular phase), menstrual phase was determined by self-reported menstrual history, as progesterone samples were not available.

PET Analysis {#s9}
============

**Volumes of Interest**Volumes of interest (VOI) were selected automatically in individual subject SPGR MRI volumes using FSL (FMRIB Software Library; [@CIT0031]) FIRST tool ([@CIT0045]) for subcortical regions and Freesurfer tool ([@CIT0016]) for cortical regions. Automated VOI were manually edited to suit the structures of interest, using a locally developed VOI tool (VOILand). Refined VOI were transferred from MRI to PET spaces according to MRI to PET coregistration parameters obtained from the co-registration module of SPM12 (Statistical Parametric Mapping; [@CIT0005]). The VOI of PET space were applied to PET frames to obtain time-activity curves of regions. Head-motion correction was performed with the image co-registration module of SPM12.

Total volumes of distribution (*V*~T~) and test-retest variability were estimated for all 21 cortical VOI ([Figure 1A--B](#F1){ref-type="fig"}). In addition, the full VOI set was used in the calculation of dose-dependent inhibition ([Figure 2](#F2){ref-type="fig"}) as well as for the averaged estimates of maximum binding capacity (*B*~max~; [Figure 3](#F3){ref-type="fig"}) and inhibitor *K*~I~ ([Figure 4](#F4){ref-type="fig"}). For analysis of *V*~T~ differences (in patients vs control subjects, [Figure 5](#F5){ref-type="fig"}) and potential correlation with BPRS score (see [Supplemental Material](#sup1){ref-type="supplementary-material"}), we chose 3 cortical regions implicated in autoradiography with \[^125^I\]α-bungarotoxin (\[^125^I\]BTX) of brain of patients with schizophrenia postmortem, previously reported with significant reductions in hippocampus (\~70%, [@CIT0018]), frontal cortex (40%, [@CIT0025]), and cingulate cortex (54%, [@CIT0039]).

![Estimates of *V*~*~T~*~ and test-retest variability for *V*~*~T~*~. (A) Regional estimates of *V*~*~T~*~ for all healthy control subjects (n=21). (B) Test-retest variability of *V*~*~T~*~ in 8 healthy controls. For both panels, bars show mean ± SD. Abbreviations: Am, amygdala; CN, caudate nucleus; Cb, cerebellum; Cg, cingulate; Fr, frontal lobe; Fs, fusiform gyrus; GP, globus pallidus; Hp, hippocampus; In, insula; LG, lingular gyrus; Oc, occipital lobe; pC, paracentral; PH, parahippocampus; Pa, parietal lobe; PS, postcentral gyrus; Pc, precentral gyrus; Pr, precuneus; Pu, putamen; Tp, temporal lobe; Th, thalamus; vS, ventral striatum.](pyy02101){#F1}

![Dose-dependent inhibition with DMXB-A level. The saturation, *s*, reflects the fraction of receptor occupied by the blocking agent, DMXB-A. Each point on the curve represents individual measurements of the plasma level of DMXB-A, determined by HPLC mass spectroscopy, and the fraction of receptors occupied by DMXB-A, estimated by the Extended Inhibition Plot (EIP). The horizontal error bars represent the SEM from 3 measurements, and the vertical error bars reflect the SEM from the linear analysis of the Extended Inhibition plot. These data were fit to the Michaelis-Menten equation, with *O*~*max*~ assigned to a value of 1; (i.e, 100% occupancy, or a saturation fraction, *s*=1). This is typical for receptor occupancy studies with PET. However, further studies at higher plasma concentrations may indicate a lower maximal occupancy, due to the unique nature of the α7 subunit, as stated in the Discussion.](pyy02102){#F2}

![Regional binding potentials (*BP*~*ND*~). The analysis using the Extended Inhibition Plot (EIP) revealed that the *BP*~*ND*~ decreased significantly in response to competition with DMXB-A by 31% in average compared with baseline. Each line on the graphs of 6 representative regions of the original 21 regions displays the estimates of BP~ND~ in individual subjects at baseline and inhibition condition.](pyy02103){#F3}

![*B* ~*max*~ estimates. Average *B*~*max*~ across all regions (21 VOIs total) were computed from the known *BP*~*ND*~ estimates, the plasma concentration of DMXB-A and the receptor affinity, *K*~*D*~, which was calculated as 0.35 nM based on known values from ^125^I α--bungarotoxin in vitro studies. The analysis reveals that the average *B*~*max*~ across all regions ranged from 0.76 to 0.96 nM in the 5 subjects, and the *K*~*i*~ ranged from 170 to 385 nM.](pyy02104){#F4}

![Distribution of V~T~ in healthy patients and controls. Boxplots of the distribution of V~T~ in healthy controls (HC) and patients with schizophrenia (SCZ) in cingulate cortex (Cg), hippocampus (Hp), and frontal cortex (Fr). The single points above the limits of the boxplot are outliers.](pyy02105){#F5}

**Kinetic Analysis**Quantification of \[^18^F\]ASEM steady-state volumes of distribution (*V*~T~) proceeded as previously published ([@CIT0062]). Specifically, the plasma reference graphical analysis was used to obtain regional *V*~T~ values that served as primary outcome variable for test-retests and analyses with age, sex, and neuropsychiatric testing as well as serving as secondary outcome variable for estimates of the reference volume of nondisplaceable bound radioligand (*V*~ND~), competitor saturation of receptors (*s*), binding potentials (*BP*~ND~), and *B*~max~. We completed *B*~max~ and affinity (IC~50~, *K*~I~) estimates of α7-nAChR in 3 steps in 5 subjects by means of DMXB-A inhibition.

We estimated the occupancy of the partial agonist inhibitor by means of estimates of the radioligand's volume of nondisplaceable distributed tracer in the baseline (*V*~ND~), obtained from baboon brain *in vivo* ([@CIT0029]), using the conventional Inhibition Plot (IP) of [@CIT0022]. We compared the value of *V*~ND~ obtained from the decline of the magnitude of the total volume of *V*~T~ in in the presence of 2 different concentrations of SR180711, of which we used the value associated with the lower dose to avoid affecting the value of *V*~ND~ by changes of protein binding in brain tissue or circulation or both (see [supplemental Figure B](#sup1){ref-type="supplementary-material"} illustrating the *V*~*ND*~ determination in baboon brain).

Applied to regional *V*~T~, the IP yielded reference volumes (*V*~ND~) and degrees of saturation (*s*), according to the equation ([@CIT0046]),

$$V_{\text{T(i)}} = \left( {1 - s} \right)~V_{\text{T}(\text{b})} + sV_{\text{ND}}$$

where *V*~T\ (b)~ symbolizes the volume of distribution at baseline and *V*~T\ (i)~ the volume at inhibition in presence of DMXB-A that competes with the radiotracer for binding to the binding site. According to Equation (1), when the regional estimates of *V*~T~ in the inhibition condition were plotted as functions of the estimates in the baseline condition, the solution yielded the reference volume, *V*~ND~, and the fraction of receptors occupied by the competitive drug, *s*.

The initial analysis revealed *V*~T~ estimates before and after DMXB-A inhibition of similar magnitudes, compensating for values of *V*~*ND*~ that may be different in the inhibition and baseline conditions. To resolve this issue, we applied the Extended IP equation (EIP; [@CIT0046]) that relates the radioligand distribution volumes at inhibition and baseline as follows:

$$V_{\text{T}{(\text{i})}} = \left( {1 - s} \right)\left\lbrack \frac{V_{\text{ND(i)}}}{V_{\text{ND(b)}}} \right\rbrack V_{\text{T(b)}} + sV_{\text{ND(i)}}$$

where values of *V*~*ND*~ at baseline and inhibition are different, denoted *V*~ND\ (b)~ and *V*~ND\ (b)~ at baseline and inhibition, respectively. The EIP yielded the value of *V*~ND~ in the inhibition condition (*V*~ND(i)~), when the true reference volume at baseline (*V*~ND(b)~) is known such that estimates yielded by EIP depend on a measure of the magnitude of the reference volume.

Volumes of distribution (*V*~T~ and *V*~ND~) yielded *BP*~ND~. We estimated the *BP*~ND~ of 5 subjects with DMXB-A inhibition in the baseline and at inhibition, using the values of *V*~T(b)~ and *V*~ND(b)~ in the baseline condition and the values of *V*~T(i)~ and *V*~ND(i)~ at inhibition obtained by means of Equation (2), in the unblocked and DMXB-A inhibited states, with the equation

$$BP_{\text{ND(b)}} = \frac{V_{\text{T(b)}}}{V_{\text{ND(b)}}} - 1\text{and}\text{BP}_{\text{ND(i)}} = \frac{V_{\text{T(i)}}}{V_{\text{ND(i)}}} - 1$$

where the *BP*~ND\ (b)~ and *BP*~ND(i)~ terms symbolize the *BP*~ND~ at baseline and inhibition, respectively.

The *BP*~ND~ and inhibitor concentrations (*C*i) yielded the *B*~max~ and *K*~I~ (IC~50~) estimates of the receptor and inhibitor, respectively. We completed *B*~max~ and affinity of the competitor (IC~50~, *K*~I~) calculation of α7-nAChR in 5 subjects by means of DMXB-A inhibition using the values of BP~ND~ of baseline and inhibition that led to the novel (never previously published) *in vivo* estimate of the magnitude of the *B*~max~ and *K*~I~ of nAChR in humans, using the equation

$$\text{BP}_{\text{ND}} = \frac{B_{\text{max}}}{K_{\text{d}}\left( {1 + \frac{\left\lbrack \text{DMXB-A} \right\rbrack}{K_{\text{I}}}} \right)}$$

where the *B*~max~ is determined relative to the affinity of the radioligand to the receptor, *K*~d~, with known values of the inhibitor concentration \[DMXB-A\] and the receptor's affinity for inhibitor, *K*~I~. For this calculation, we used a calculated value of ASEM *K*~d~ of 0.35 nM (established from prior measure of *K*~I~ of 0.4 nM for \[^123^I\] bungarotoxin) ([@CIT00640]).

Schizophrenia {#s10}
-------------

As a feasibility study, we compared 6 patients with schizophrenia to a subset of 15 healthy volunteers matched for age, within 3 specific brain regions: hippocampus and cingulate and frontal cortices. In this subset, the mean age of healthy volunteers was 23±4 (SD) y, range 18 to 30, and for patients with schizophrenia the mean age was 24±4 (SD) y, range 20--31 y.

Results {#s11}
=======

Regional *V*~T~ {#s12}
---------------

Regional estimates of *V*~T~ in selected regions are shown in [Figure 1A](#F1){ref-type="fig"}. We tested the test-retest variability of the *V*~T~ estimates in 8 healthy subjects, 6 males (average age 41) and 2 females (average age 24 y). Across all cortical and subcortical VOIs, the average test-retest variability was 7.8%±0.6% (SD, see [Figure 1B](#F1){ref-type="fig"}), ranging from 6.5% to 8.9% (repeatability of \>90%).

Receptor Kinetics {#s13}
-----------------

The reanalysis of inhibition of \[^18^F\]ASEM binding in baboon ([@CIT0029]) yielded the V~T~ of nondisplaceable tracer accumulation at baseline (*V*~ND(b)~), In the baboon, the *V*~T~ of \[^18^F\]ASEM declined markedly in response to blocking with the high affinity inhibitor SSR180711. The reference volume *V*~ND~ assessed by means of the standard IP is presented in [Figure 2](#F2){ref-type="fig"}, with the estimate of *V*~ND\ (b)~ of 5.4 ml/cm^3^ at the lower dose of the SR180711. We note that the magnitude of *V*~ND~ is a property of the tracer \[^18^F\]ASEM that we assume to be representative of mammalian brains in general.

We used the value of *V*~ND~ of 5.4 mL/cm^3^ as the value of *V*~ND\ (b)~ in the EIP, required when V~T~ values failed to yield evidence of inhibition of radioligand binding by DMXB-A in human brain. In 5 subjects, the value of V~ND(b)~ yielded estimates of saturation (*s*) and inhibition reference volume (*V*~ND(i)~), as shown in [Figure 2](#F2){ref-type="fig"} of the individual estimates of *s* as function of the concentration of DMXB-A in arterial plasma, confirming the dose-dependent inhibition exerted by DMXB-A. Estimates of regional *BP*~ND~ declined significantly in 6 of the 21 representative regions after blocking with DMXB-A, as shown in [Figure 3](#F3){ref-type="fig"}. The average values for all 21 regions of *B*~max~ and average values of the receptor's *K*~I~ to DMXB-A ranged from 0.67 to 0.82 nM for *B*~max~ and from 170 to 385 nM for *K*~I~, as presented in [Figure 4](#F4){ref-type="fig"}. Regarding the choice of the *V*~ND\ (b),~ the standard error of the *V*~ND\ (b)~ estimate in baboon of 2.7 mL/cm^3^ corresponded to ranges of human *B*~max~ estimates of 0.4 to 1.9 nM and DMXB-A *K* estimates of 138 to 363 nM.

Menstrual Cycle {#s14}
---------------

The menstrual cycle phase (luteal vs follicular) was determined for the 8 healthy control females. Estimates of *V*~T~ did not differ significantly in relation to cycle phase. The lower ages of women volunteers precluded analysis of different changes of *V*~T~ with age in men and women.

Schizophrenia {#s15}
-------------

To evaluate the feasibility of studying patients with schizophrenia, we compared patients with healthy control subjects. In the 3 preselected regions (cingulate and frontal cortices, hippocampus) examined for group differences between patients and the age-matched control subjects, the median *V*~T~ values were lower in patients than in age-matched healthy volunteers ([Figure 5](#F5){ref-type="fig"}). Potential outliers, one a control subject and one a patient, were identified (outlier points marked in boxplots of [Figure 5](#F5){ref-type="fig"}). Using the Mann-Whitney U-test, we tested for significant differences in median *V*~T~ values between control subjects and patients, before and after excluding outliers. The results, with corrections for multiple comparisons, are given in [Table 2](#T2){ref-type="table"}. In the cingulate cortex and hippocampus, the difference in *V*~T~ was significant after exclusion of outliers and correction for multiple comparisons (*P*=.02 in both regions).

###### 

Corrected and Uncorrected *P* Values from *V*~*T*~ in Controls vs Patients Results

(uncorrected *P* values and corrected by different methods) of Mann-Whitney tests for V~T~ in Healthy Controls vs Patients with Schizophrenia

  Region                  Uncorrected *P* value   Adjusted (Horchberg)   Adjusted (Bonferroni)   Adjusted (Simes)
  ----------------------- ----------------------- ---------------------- ----------------------- ------------------
  All Data                                                                                       
   Cg                     .056                    .159                   .167                    .118
   Fr                     .171                    .172                   .515                    .172
   Hp                     .079                    .159                   .238                    .119
  With outliers removed                                                                          
   Cg                     .009                    .028                   .028                    .025
   Fr                     .058                    .058                   .173                    .058
   Hp                     .017                    .033                   .05                     .025

Adjusted *P* values were obtained by the STATA package qqvalue using 3 different methods of adjustment ([@CIT0066]; specific methods are Horcberg, 1998, standard Bonferroni correction and Simes, 1986).

The correlation of estimates of *V*~T~ with scores of BPRS did not reach statistical significance, although there were positive trends for values in cingulate and frontal cortices in 5 subjects after outlier analyses (see [supplementary Figure C](#sup1){ref-type="supplementary-material"} for details).

Antipsychotic Medication {#s16}
------------------------

The biodistribution in mice revealed no significant effects on \[^18^F\]ASEM binding of aripriprizole, risperidone, or olanzapine (see [Supplemental Materials](#sup1){ref-type="supplementary-material"}). As described in Methods, the patient with schizophrenia chronically treated with risperidone had repeated PET after a 3-week drug-free period, imposed for clinical reasons. The *V*~T~ estimates did not differ by more than 7% (i.e., within the test-retest variability of control subjects in any brain region for the on- and off--risperidone comparison ([Figure 1B](#F1){ref-type="fig"}) ([supplementary Figure D](#sup1){ref-type="supplementary-material"}, points labelled "on" and "off").

Discussion {#s17}
==========

Subjects {#s18}
--------

We extended the first-in-human report of [@CIT0062] from 5 to 21 healthy subjects (8 test-retest sessions, 5 sessions with inhibition by DMXB-A of \[^18^F\]ASEM binding, and 6 baseline sessions) and added a preliminary study of 6 patients with schizophrenia, with 1 patient receiving test-retest PET in the absence and presence of chronic risperidone medication.

The results demonstrate excellent test-retest repeatability of \[^18^F\]ASEM PET of \>90%. In the population of 21 healthy nonsmoking volunteers, when we plotted tracer distribution volume *V*~*T*~ against age, we observed an increase with of *V*~*T*~ with age. While our smaller sample and lack of a wide age distribution limited our ability to test this relationship formally with regression analysis, the trends in our data match the findings from a larger age range in another set of subjects ([@CIT0008], which had only 2 subjects in common that we provided to the Coughlin paper previously). The preliminary findings of values of *V*~*T*~ vs age are shown in [supplementary Figure D](#sup1){ref-type="supplementary-material"}.

We were unable to determine sex differences because of the different age ranges. Of the 8 women, none of them showed a specific effect of menstrual cycle on estimates of *V*~*T*~.

Receptor *BP*~ND~ {#s19}
-----------------

Estimates of *B*~max~ are based on determination of *BP*~ND~ ([@CIT0023]). Importantly, for the first time, we present evidence that competitor occupancy, apparent *K*~I~, and *B*~max~ of human α7-nAChR can be measured, based on the assumptions presented. We determined regional estimates of \[^18^F\] ASEM binding as the first step towards complete receptor quantification. In addition to regional values of *V*~T~, the receptor quantification required knowledge of the magnitude of *V*~T~ of the tracer in a region of brain tissue with no specific binding. Previously, no such reference volume has been identified for this tracer with prevalent binding in cerebral cortex. As the first PET study with blockade of α7-nAChR in human brain *in vivo*, this study took advantage of the original development of the well-documented partial agonist DMXB-A at the University of Florida ([@CIT0032]; [@CIT0033]) and the subsequent successful testing in patients with schizophrenia at the University of Colorado ([@CIT0042]; [@CIT0017]).

Receptor Occupancy {#s20}
------------------

Recent studies of mouse and baboon brains revealed significant blockade of the α7-nAChR by the high-affinity partial α7-nAChR agonists SSR180711 and DMXB-A *in vivo* ([@CIT0029]a; [@CIT0062]), but effective inhibition or competition has not yet been confirmed in humans. As a candidate drug, DMXB-A was tested in clinical trials of patients with schizophrenia, Alzheimer's disease, or ADHD ([@CIT0019]; [@CIT0017]), and the drug was used here to test target engagement/occupancy *in vivo* at the α7-nAChR and to demonstrate specificity of \[^18^F\]ASEM binding to these receptors.

Previously, we demonstrated dose-dependent tracer inhibition in rodents by DMXB-A with cerebellum as reference region (appropriate in rodents but not human brain) ([@CIT0062]). Similarly, in the present study, blockade with the highest dose of DMXB-A allowed in humans (150 mg orally) exhibited competition with binding of \[^18^F\]ASEM. The occupancy of receptors by DMXB-A displayed a relatively monotonic relationship with plasma levels of DMXB-A.

We used the EIP under the assumption that the apparently absent inhibition of receptor binding would be due to factors such as change of free fractions of the radioligand in circulation or brain tissue or both, with the consequence that the value of *V*~ND~ would differ between the baseline (*V*~ND\ (b)~) and inhibited (*V*~ND\ (a)~) states, as reported by [@CIT0046]. Using EIP and the value of *V*~ND(b)~ of 5.4 mL/cm^3^ obtained from moderate blockade of the α7-nAChR in baboon brain, reported by [@CIT0029] as a simple reduction in slope and reanalyzed by the standard IP here, we obtained DMXB-A occupancies in the human subjects in the range of 17% to 49%. Future studies with new α7-nAChR drugs will further test the occupancy and the accuracy of the resulting estimates of *B*~max~ and affinity in human brain *in vivo*.

With the assumptions and translation from autopsy protein and wet tissue-based *B*~max~ of α7-nAChR, we find remarkable agreement among the *B*~max~ estimates that we regard as another innovative aspect of the present study. As 150 mg is the highest single oral dose allowed under the DMXB-A IND based on historical information, we elected not to test lower doses, because of the modest occupancy, compared with occupancy of drugs such as antipsychotics, and more recently glycine transporter (GlyT1) ligands ([@CIT0038]; [@CIT0061]). However, the dose dependent occupancy with DMXB-A is evidence of specificity of the radiotracer \[^18^F\]ASEM in human brain. The occupancy is further evidence of the potential usefulness of \[^18^F\]ASEM for therapeutic occupancy trials, as these are somewhat complicated due to the inverted-U-shaped dose effect of α7-nAChR partial agonists ([@CIT0065]).

The α7-nAChR receptor has 5 binding sites among the 5 α7 subunits and is maximally activated when at least 2 binding sites are occupied by an agonist. At higher doses, agonists bind at up to all 5 binding sites and progressively desensitize the α7. Moreover, α7 partial agonist drugs such as DMXB-A and others produce their clinical effects at lower concentrations than would be expected from in vitro functional experiments where peak currents are recorded ([@CIT0050]; [@CIT0043]; [@CIT0049]). The co-agonistic mechanism of *in vivo* action of α7 partial agonist suggests that DMXB-A, at the clinically effective dose, binds at 1 of 5 binding sites of α7, while brisk activation of the receptor will, however, occur upon exposure to endogenous ACh. Thus, *in vivo*, a single molecule of DMXB-A plus 1 molecule of ACh are sufficient to trigger the opening of the α7-nAChR channel ([@CIT0059]; [@CIT0050]; [@CIT0043]; [@CIT0049]). Therefore, in the PET occupancy studies with the DMXB-A-treated humans, the binding of \[^18^F\]ASEM is expected to be inhibited by as little as 20% to 40% (one-fifth to two-fifths) instead of 100%. This co-agonistic mechanism agrees reasonably with our PET \[^18^F\]ASEM inhibition by DMXB-A in humans at 17% to 49% with a maximum clinical dose of DMXB-A (150 mg). Full blocking of \[^18^F\]ASEM with α7 agonists occurs at higher doses, as observed in mice with 20 mg/kg DMXB-A ([@CIT0029]a; [@CIT0062]) and in baboons administered 5 mg/kg of the more highly potent SSR180711 that is unavailable in the United States for human use ([@CIT0029]).

Receptor Density and Tracer Affinity {#s21}
------------------------------------

The use of the EIP with the DMXB-A inhibition and the use of the estimate of *V*~ND~ from baboon brain ([@CIT0029]) yielded the binding potentials necessary to estimate the average values across all binding regions of *B*~max~ (0.67--0.82 nM) and *K*~I~ (range 170--385) in human brain. While the value of *V*~ND~ in humans currently is unknown, the baboon value of 5.4 mL/cm^3^ estimated here with SEM of 2.7 mL/cm^3^ corresponded to ranges of *B*~max~ estimates of 0.75 (range 0.38--1.83) nM and DMXB-A *K*~I~ estimates of 138 to 363 nM. These values agree favorably with estimates postmortem of 0.28 nM *B*~max~ for human cerebral cortex with α-\[^125^I\]bungarotoxin ([@CIT0011]) and cortical *B*~max~ values of 0.7 nM in patients with schizophrenia compared with 1.5 nM in healthy control subjects ([@CIT0039]), assuming 10% mg protein converted to wet weight.

Schizophrenia {#s22}
-------------

In the feasibility study of 6 patients with schizophrenia, we observed reductions of *V*~*T*~ in 5 of the 6 subjects. The finding of significant reduction of regional distribution in 5 of 6 subjects in 2 of 3 regions after outlier exclusion of a single subject agreed with previous findings postmortem. However, in the present study, the difference between controls and patients is lower than observed postmortem. This finding could be due to a number of factors, such as tracer differences (\[^18^F\]-ASEM vs \[^125^I\]-BTX), in vivo vs in vitro tests, and the heterogeneity of the patient population.

Limitations {#s23}
===========

**Antipsychotic Medication**Neuroreceptor studies of patients with schizophrenia in the drug free or naïve state are increasingly logistically challenging, although such studies have been completed in limited populations ([@CIT0015]; [@CIT0060]). In the present limited population, patients with schizophrenia were tested while on stable medication for more than 3 weeks with antipsychotics that are held to have only negligible effect on binding to α7 nAchR and to be nonexclusionary in therapeutic studies of partial agonists such as DMXB-A, e.g., clozapine (which was exclusionary). Several precautions were taken to reduce the possibility of confounding antipsychotic action in the quantification of binding to α7nAchR. First, the majority of the patients were treated with risperidone and haloperidol, which unlike clozapine fail to normalize the P50 abnormality ([@CIT0001]). Second, a rodent biodistribution study found no significant effects on \[^18^F\]ASEM binding. Finally, although only 1 subject was studied off medications, the repeated PET test on and off chronic risperidone was suggestive of the conclusion that this commonly used antipsychotic is unlikely to confound the estimates of the *V*~T~ values for ~α7~ nAChR.

Effects of Smoking {#s24}
------------------

All 21 control subjects and 5 of the 6 patients with schizophrenia were nonsmokers. We considered comparing smokers with nonsmokers but did not recruit a sufficient number of healthy volunteers with clinically verified smoking status. By design therefore we studied only nonsmoking control subjects in the current protocol of test-retest and occupancy studies and comparison with the feasibility study of 6 patients with schizophrenia.

Despite the relatively high prevalence of smoking in patients with schizophrenia, only 1 of the subjects randomly recruited with schizophrenia smoked (20 cigarettes/d). Most subjects were younger (\<35 years old), which may be a contributing factor, as it has been reported that younger subjects are less likely to smoke (for an example of this trend, see <https://www.hhs.gov/ash/oah/adolescent-development/substance-use/drugs/tobacco/trends/index.html>). The patient that happened to be a regular smoker also happened to be the oldest of the patients at 31 y (age range of patients 20--31 y, mean 24.9 y). The *V*~T~ values did not differ significantly for the smoking subject compared with the other patients with schizophrenia with low value of *V*~T~.

Furthermore, on the day of PET, all control subjects and patients with schizophrenia had CO values \<4 PPM, indicating successful abstinence (regardless of their self-reports) and likely longer than 12 h, reducing the acute effects of nicotine, if any, on the PET measure of the tracer *V*~T~.

As a future direction, we specifically will recruit participants for inclusion into cohorts of smokers and nonsmokers of both healthy controls and patients with schizophrenia to further explore smoking effects. The assignments will be verified by smoking history, urine cotinine levels, CO breath measures, and assessments of extent of nicotine use and dependence (e.g., Fagerstrom, MINI nicotine use, Minnesota Nicotine Scale, and Michigan Nicotine Reinforcement Questionnaire). With a larger sample, the schizophrenia group is likely to comprise more smokers, particularly among older patients.

Age and Sex Differences {#s25}
-----------------------

In the group of 21 subjects in the age range of 18 to 50 y, males and females were not distributed uniformly, ruling out formal determination of sex differences as functions of normal aging. Also, the small number of 5 subjects with DMXB-A occupancy nonetheless yielded a reasonable range of DMXB-A human plasma concentrations, presumably due to individual variability in oral absorption and metabolism of the inhibitor.

Schizophrenia {#s26}
-------------

In this feasiblity study, the small number of patients with schizophrenia is a statistical limitation. In 5 of the 6 subjects, estimates of *V*~T~ in 2 of 3 regions compared with age-matched control subjects, as well as a formal outlier analysis, suggested that the high values of *V*~T~ in one subject may have had other causes leading to the elevation. Thus, expansion of the number of patients with schizophrenia and detailed documentation of the clinical and neuropsychological features of the patients will help expand the findings of factors that influence the heterogeneity of α7nAchR findings.

Conclusions {#s27}
===========

Here, we confirmed the test-retest reliability of tracer binding in healthy human brains, and we demonstrated for the first-time specificity of competition from the partial agonist DMXB-A in normal healthy volunteers, as previously reported in preclinical imaging studies. The novel first time presentation of *in vivo* B~max~ measures agreed favorably with published human postmortem values. The effects of antipsychotics in our schizophrenia volunteers may not be a major confound based on our preliminary mice and literature and one subject on and off risperidone. The preliminary findings in patients with schizophrenia suggest the feasibility of imaging this important disorder and generally consistent with previous reports of human brains postmortem, but clearly larger samples with a spectrum of clinical severity and comparisons with full cognitive and neuropsychological tests are needed.
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